A total of 545 subjects with episodic or chronic migraine, who are aged 18 and above, were included in the trial.

(Reuters) -AbbVie said on Wednesday its migraine drug met the main goal and was superior to a widely used generic treatment ...

AbbVie (NYSE:ABBV) recently announced positive results from its Phase 3 TEMPLE study, marking significant progress in ...

AbbVie said on Monday its treatment for a group of blood cancers failed to meet the main goal of significantly improving the ...

AbbVie's atogepant showed fewer side effects and greater efficacy than topiramate in a Phase 3 migraine prevention trial.

AbbVie's Phase 3 VERONA trial in HR-MDS showed no overall survival benefit for venetoclax-azacitidine; existing uses of ...

AbbVie is deploying more capital into its pipeline, which features 50 programs in mid- and late-stage development and over ...

Results from the Phase III TEMPLE trial show that patients administered Qulipta (atogepant) experienced significantly fewer ...

Two Democratic lawmakers have renewed accusations that large pharma companies have evaded paying U.S. taxes through a ...

AbbVie combines high yield, strong growth from Rinvoq and Skyrizi, and a solid pipeline to support dividends and returns.

AbbVie Golden Ticket Comes to a ClosePress release2025-06-18 11:48AbbVie Golden Ticket ceremony at SmiLe Venture Hub.Lund, Sweden – The one-year AbbVie Golden Ticket program has officially concluded – ...

AbbVie said on Wednesday its migraine drug met the main goal and was superior to a generic drug in a head-to head late-stage ...